Ambu gets US approval for new product
Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
The US Food and Drug Administration (FDA) has approved Ambu's product Vivasight 2 DLT, a ventilation tube with a camera, for single-use purposes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst believes in continued progress for Ambu
For subscribers
Olympus launches line of single-use scopes
For subscribers
